Lexicon Pharmaceuticals’ (LXRX) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report issued on Wednesday, Benzinga reports.

Other equities research analysts have also issued reports about the company. Leerink Partners set a $6.00 price objective on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a research report on Tuesday, July 9th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Lexicon Pharmaceuticals Stock Down 37.4 %

Shares of LXRX opened at $1.22 on Wednesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 11.51 and a quick ratio of 11.49. The stock has a market capitalization of $300.41 million, a price-to-earnings ratio of -1.56 and a beta of 1.28. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.73. The business’s 50 day simple moving average is $1.72 and its 200-day simple moving average is $1.76.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. The firm had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $2.74 million. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. During the same period in the prior year, the company earned ($0.22) EPS. As a group, equities analysts expect that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. CVI Holdings LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at approximately $34,000. Principal Financial Group Inc. raised its position in Lexicon Pharmaceuticals by 116.1% during the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 12,225 shares in the last quarter. Great Point Partners LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth $50,000. SG Americas Securities LLC grew its position in shares of Lexicon Pharmaceuticals by 107.6% during the 3rd quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 23,893 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Lexicon Pharmaceuticals by 44.5% during the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 13,972 shares during the period. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.